Dynavax Technologies (NASDAQ:DVAX) Receives Buy Rating from HC Wainwright

Dynavax Technologies (NASDAQ:DVAX – Get Free Report)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research report issued to clients and investors on Friday,Benzinga reports. They currently have a $31.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price target would suggest a potential upside of 132.56% from the company’s current […]